Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

MLA

Dayan, Gustavo H., et al. “Efficacy of a Bivalent (D614 + B.1.351) SARS-CoV-2 Recombinant Protein Vaccine with AS03 Adjuvant in Adults: A Phase 3, Parallel, Randomised, Modified Double-Blind, Placebo-Controlled Trial.” The Lancet Respiratory Medicine, no. Preprints, Jan. 2023. EBSCOhost, https://doi.org/10.1016/S2213-2600(23)00263-1.

APA

Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N., Allen, M., Antony, J., Asante, K. P., Bhate, A. S., Beresnev, T., Bonaparte, M. I., Celle, M., Ceregido, M. A., Corey, L., Dobrianskyi, D., Fu, B., Grillet, M.-H., Keshtkar-Jahromi, M., Juraska, M., … Zhang, N. (2023). Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. The Lancet Respiratory Medicine, Preprints. https://doi.org/10.1016/S2213-2600(23)00263-1

Chicago

Dayan, Gustavo H, Nadine Rouphael, Stephen R Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen, Johannes Antony, et al. 2023. “Efficacy of a Bivalent (D614 + B.1.351) SARS-CoV-2 Recombinant Protein Vaccine with AS03 Adjuvant in Adults: A Phase 3, Parallel, Randomised, Modified Double-Blind, Placebo-Controlled Trial.” The Lancet Respiratory Medicine, no. Preprints (January). doi:10.1016/S2213-2600(23)00263-1.